{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T06:54:22Z","timestamp":1793084062219,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1245\/s10434-025-17988-1","type":"journal-article","created":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T17:33:40Z","timestamp":1755970420000},"page":"8844-8855","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Comparison between Neoadjuvant Chemoradiotherapy and Chemotherapy for Patients with Resectable Pancreatic Cancer"],"prefix":"10.1245","volume":"32","author":[{"given":"Takashi","family":"Murakami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryusei","family":"Matsuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Oshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Yabushita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Sho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiaki","family":"Unno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Isaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goro","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suguru","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohei","family":"Satoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Ohtsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Yamaue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takukazu","family":"Nagakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5520-8114","authenticated-orcid":false,"given":"Itaru","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,23]]},"reference":[{"issue":"6","key":"17988_CR1","first-page":"394","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin."},{"issue":"1","key":"17988_CR2","first-page":"7","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2018;68(1):7\u201330.","journal-title":"CA Cancer J Clin."},{"issue":"4","key":"17988_CR3","doi-asserted-by":"publisher","first-page":"e1000267","DOI":"10.1371\/journal.pmed.1000267","volume":"7","author":"S Gillen","year":"2010","unstructured":"Gillen S, Schuster T, Meyer Zum B\u00fcschenfelde C, Friess H, Kleeff J. Preoperative\/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7(4):e1000267.","journal-title":"PLoS Med."},{"issue":"2","key":"17988_CR4","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/SLA.0000000000002705","volume":"268","author":"JY Jang","year":"2018","unstructured":"Jang JY, Han Y, Lee H, et al. Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2\/3 trial. Ann Surg. 2018;268(2):215\u201322.","journal-title":"Ann Surg."},{"key":"17988_CR5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1200\/JCO.2019.37.4_suppl.189","volume":"37","author":"M Unno","year":"2019","unstructured":"Unno M, Motoi F, Matsuyama Y, et al. Randomized phase II\/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02\/JSAP-05). J Clin Oncol. 2019;37:189.","journal-title":"J Clin Oncol."},{"issue":"5","key":"17988_CR6","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1200\/JCO.2016.68.5081","volume":"35","author":"AA Mokdad","year":"2017","unstructured":"Mokdad AA, Minter RM, Zhu H, et al. Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis. J Clin Oncol. 2017;35(5):515\u201322.","journal-title":"J Clin Oncol."},{"issue":"6","key":"17988_CR7","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/jhbp.348","volume":"23","author":"F Miura","year":"2016","unstructured":"Miura F, Yamamoto M, Gotoh M, et al. Validation of the board certification system for expert surgeons (hepato-biliary-pancreatic field) using the data of the National Clinical Database of Japan: part 2\u2014Pancreatoduodenectomy. J Hepatobiliary Pancreat Sci. 2016;23(6):353\u201363.","journal-title":"J Hepatobiliary Pancreat Sci."},{"issue":"6","key":"17988_CR8","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/jhbp.344","volume":"23","author":"F Miura","year":"2016","unstructured":"Miura F, Yamamoto M, Gotoh M, et al. Validation of the board certification system for expert surgeons (hepato-biliary-pancreatic field) using the data of the National Clinical Database of Japan: part 1\u2014Hepatectomy of more than one segment. J Hepatobiliary Pancreat Sci. 2016;23(6):313\u201323.","journal-title":"J Hepatobiliary Pancreat Sci."},{"key":"17988_CR9","unstructured":"National Comprehensive Cancer Network clinical practice guidelines in oncology. Pancreatic adenocarcinoma, version 2. 2016."},{"issue":"11","key":"17988_CR10","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/archsurg.1992.01420110083017","volume":"127","author":"DB Evans","year":"1992","unstructured":"Evans DB, Rich TA, Byrd DR, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992;127(11):1335\u20139.","journal-title":"Arch Surg."},{"key":"17988_CR11","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Liti\u00e8re S, de Vries E, et al. (2016) RECIST 1.1-Update and clarification: From the RECIST committee. Eur J Cancer. 2016;62:132\u20137.","journal-title":"Eur J Cancer."},{"issue":"2","key":"17988_CR12","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205\u201313.","journal-title":"Ann Surg."},{"issue":"6","key":"17988_CR13","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1245\/s10434-019-08156-3","volume":"27","author":"AI Al Abbas","year":"2020","unstructured":"Al Abbas AI, Zenati M, Reiser CJ, et al. Serum CA19-9 response to neoadjuvant therapy predicts tumor size reduction and survival in pancreatic adenocarcinoma. Ann Surg Oncol. 2020;27(6):2007\u201314.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"17988_CR14","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s12957-017-1240-2","volume":"15","author":"M Dhir","year":"2017","unstructured":"Dhir M, Malhotra GK, Sohal DPS, et al. Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients. World J Surg Oncol. 2017;15(1):183.","journal-title":"World J Surg Oncol."},{"issue":"6","key":"17988_CR15","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1002\/cam4.1071","volume":"6","author":"HX Zhan","year":"2017","unstructured":"Zhan HX, Xu JW, Wu D, et al. Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of prospective studies. Cancer Med. 2017;6(6):1201\u201319.","journal-title":"Cancer Med."},{"issue":"13","key":"17988_CR16","doi-asserted-by":"publisher","first-page":"4498","DOI":"10.1245\/s10434-019-07735-8","volume":"26","author":"H Eguchi","year":"2019","unstructured":"Eguchi H, Takeda Y, Takahashi H, et al. A prospective, open-label, multicenter phase 2 trial of neoadjuvant therapy using full-dose gemcitabine and s-1 concurrent with radiation for resectable pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2019;26(13):4498\u2013505.","journal-title":"Ann Surg Oncol."},{"key":"17988_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3389\/fonc.2020.00041","volume":"10","author":"QP Janssen","year":"2020","unstructured":"Janssen QP, O\u2019Reilly EM, van Eijck CHJ, Groot Koerkamp B. Neoadjuvant treatment in patients with resectable and borderline resectable pancreatic cancer. Front Oncol. 2020;10:41.","journal-title":"Front Oncol."},{"issue":"16","key":"17988_CR18","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1200\/JCO.19.02274","volume":"38","author":"E Versteijne","year":"2020","unstructured":"Versteijne E, Suker M, Groothuis K, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch Randomized Phase III PREOPANC trial. J Clin Oncol. 2020;38(16):1763\u201373.","journal-title":"J Clin Oncol."},{"issue":"2","key":"17988_CR19","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1093\/jjco\/hyy190","volume":"49","author":"F Motoi","year":"2019","unstructured":"Motoi F, Kosuge T, Ueno H, et al. Randomized phase II\/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02\/JSAP05). Japanese J Clin Oncol. 2019;49(2):190\u20134.","journal-title":"Japanese J Clin Oncol."},{"issue":"6","key":"17988_CR20","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1245\/s10434-018-07131-8","volume":"26","author":"Y Nagakawa","year":"2019","unstructured":"Nagakawa Y, Sahara Y, Hosokawa Y, et al. Clinical impact of neoadjuvant chemotherapy and chemoradiotherapy in borderline resectable pancreatic cancer: analysis of 884 patients at facilities specializing in pancreatic surgery. Ann Surg Oncol. 2019;26(6):1629\u201336.","journal-title":"Ann Surg Oncol."},{"issue":"8","key":"17988_CR21","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1002\/bjs.10870","volume":"105","author":"E Versteijne","year":"2018","unstructured":"Versteijne E, Vogel JA, Besselink MG, et al. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. Br J Surg. 2018;105(8):946\u201358.","journal-title":"Br J Surg."},{"issue":"2","key":"17988_CR22","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/MPA.0000000000001231","volume":"48","author":"JM Cloyd","year":"2019","unstructured":"Cloyd JM, Chen HC, Wang X, et al. Chemotherapy versus chemoradiation as preoperative therapy for resectable pancreatic ductal adenocarcinoma: a propensity score adjusted analysis. Pancreas. 2019;48(2):216\u201322.","journal-title":"Pancreas."},{"issue":"10","key":"17988_CR23","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s00595-020-02028-0","volume":"50","author":"RJ Torphy","year":"2020","unstructured":"Torphy RJ, Fujiwara Y, Schulick RD. Pancreatic cancer treatment: better, but a long way to go. Surg Today. 2020;50(10):1117\u201325.","journal-title":"Surg Today."},{"issue":"25","key":"17988_CR24","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","volume":"379","author":"T Conroy","year":"2018","unstructured":"Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395\u2013406.","journal-title":"N Engl J Med."},{"issue":"10","key":"17988_CR25","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1097\/COC.0000000000000601","volume":"42","author":"A Polish","year":"2019","unstructured":"Polish A, Joseph NE, Marsh RW. Pathologic response to primary systemic therapy with FOLFIRINOX in patients with resectable pancreatic cancer. Am J Clin Oncol. 2019;42(10):761\u20136.","journal-title":"Am J Clin Oncol."},{"key":"17988_CR26","doi-asserted-by":"publisher","first-page":"102016","DOI":"10.1016\/j.ctrv.2020.102016","volume":"86","author":"D Schizas","year":"2020","unstructured":"Schizas D, Charalampakis N, Kole C, et al. Immunotherapy for pancreatic cancer: a 2020 update. Cancer Treatment Rev. 2020;86:102016.","journal-title":"Cancer Treatment Rev."},{"key":"17988_CR27","doi-asserted-by":"publisher","first-page":"101926","DOI":"10.1016\/j.ctrv.2019.101926","volume":"81","author":"E Lai","year":"2019","unstructured":"Lai E, Puzzoni M, Ziranu P, et al. New therapeutic targets in pancreatic cancer. Cancer Treatment Rev. 2019;81:101926.","journal-title":"Cancer Treatment Rev."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17988-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-17988-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17988-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T15:40:38Z","timestamp":1760715638000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-17988-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,23]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["17988"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-17988-1","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,23]]},"assertion":[{"value":"18 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}